SML3893
LCL521 dihydrochlroide
≥95% (HPLC)
Synonyme(s) :
(1R,2R)-2-N-(Tetradecanoylamino)-1-(40-nitrophenyl)-propyl-1,3-O,O-di-(N,N-dimethylamino) acetate dihydrochloride, 1,3-DMG-B13, 1,3-O,O-DMG-B13•2HCl, 1,3-di-DMG-B13, B13: (1R,2R)-2-(tetradecanoylamino)-1-(4′-nitrophenyl)-1,3-propandiol), LCL 521, LCL-521
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C31H52N4O7·2HCl
Numéro CAS:
Poids moléculaire :
665.69
UNSPSC Code:
51111800
MDL number:
NACRES:
NA.21
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
assay
≥95% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
CN(C)CC(O[C@H](C1=CC=C(C=C1)[N+]([O-])=O)[C@@H](COC(CN(C)C)=O)NC(CCCCCCCCCCCCC)=O)=O.[2HCl]
Biochem/physiol Actions
N,N-dimethyl glycine (DMG) diester prodrug form of the selective acid ceramidase (ACDase) inhibitor B13 for enhanced lysosomal delivery and cellular potency.
LCL521 is the N,N-dimethyl glycine (DMG) diester prodrug form of the selective acid ceramidase (ACDase) inhibitor B13 (no inhibition against NCDase/ASAH2 or AlkCDase/ACER2). The DMG enables efficient and targeted B13 lysosomal delivery, resulting in enhanced cellular ACDase inhibitory potency (by 70% vs 12% in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13) and effective blockage of ceramide (Cer) to sphingosine (Sph) processing (80% vs 0% Sph level drop in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13).
LCL521 is the N,N-dimethyl glycine (DMG) diester prodrug form of the selective acid ceramidase (ACDase) inhibitor B13 (no inhibition against NCDase/ASAH2 or AlkCDase/ACER2). The DMG enables efficient and targeted B13 lysosomal delivery, resulting in enhanced cellular ACDase inhibitory potency (by 70% vs 12% in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13) and effective blockage of ceramide (Cer) to sphingosine (Sph) processing (80% vs 0% Sph level drop in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13).
Disclaimer
Hygroscopic
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Mladen Korbelik et al.
International journal of cancer, 139(6), 1372-1378 (2016-05-04)
Acid ceramidase has been identified as a promising target for cancer therapy. One of its most effective inhibitors, LCL521, was examined as adjuvant to photodynamic therapy (PDT) using mouse squamous cell carcinoma SCCVII model of head and neck cancer. Lethal
Shai White-Gilbertson et al.
Journal of lipid research, 60(7), 1225-1235 (2019-04-17)
Radiation treatment failure or relapse after initial response to chemotherapy presents significant clinical challenges in cancer patients. Escape from initial courses of treatment can involve reactivation of embryonic developmental stages, with the formation of polynuclear giant cancer cells (PGCCs). This
Shai White-Gilbertson et al.
Cancer medicine, 9(9), 3142-3152 (2020-03-07)
Polyploid giant cancer cells (PGCC) represent a poorly understood, small subpopulation of tumor cells that are increasingly being recognized for their critical role in therapy resistance, metastasis, and cancer recurrence. PGCC have the potential to generate progeny through primitive or